Description of trastuzumab-emtansine extravasation and treatment

"We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation" Sallevelt et al (2020).

Abstract:

WHAT IS KNOWN AND OBJECTIVE: Trastuzumab-emtansine is an antibody-drug conjugate developed to decrease off-target toxicity. According to the product label, reactions secondary to extravasation are mild or moderate.

CASE SUMMARY: We report on a 51-year-old woman who developed epidermal necrosis after extravasation of trastuzumab-emtansine, which required surgical intervention. Six weeks later, the lesions were healed with residual hyperpigmentation.

WHAT IS NEW AND CONCLUSION: We describe the course of a case of severe toxicity following trastuzumab-emtansine extravasation. We provide treatment recommendations and recommend amending the information on the product label on extravasation.

Reference:

Sallevelt, B.T.G.M., Teunis, T., Agterof, M.J. and van den Broek, M.P.H. (2020) Extravasation of an antibody-drug conjugate: A case report of epidermal necrosis after trastuzumab-emtansine extravasation. Journal of Clinical Pharmacy and Therapeutics. May 15th. doi: 10.1111/jcpt.13148. (Epub ahead of print).

Safety IV catheter